drugset / Trial / NCT01170052
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1/2
Withdrawn
20 enrolled
Charite University, Berlin, Germany
Mundipharma K.K. · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability and activity of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma who are not eligible for high dose chemotherapy and autologous/allogeneic stem cell transplantation.
Timeline
- Start
- 2010-05
- Primary completion
- 2012-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 90 mg/m2 | Intravenous |
| Subject | Temsirolimus | Small molecule | 75 mg | Intravenous |